Verducatib

Overview

Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1 ). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis ( BE ). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lower Respiratory Inflammation | Products > Disease Areas > Respiratory Inflammation | Products > Disease Areas > Bronchitis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Cathepsin | Products > Signaling Pathways > Dipeptidyl Peptidase

Product Information

• Catalog No.: HY-172242
• CAS No.: 1887236-33-0
• Molecular Formula: C31H35FN4O3
• Molecular Weight: 530.63
• Purity: 98.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source